tiprankstipranks
Takeda Pharmaceutical Company (TAK)
NYSE:TAK
US Market
TAK
Takeda Pharmaceutical Company
RESEARCH TOOLSreports
Want to see TAK full AI Analyst Report?

Takeda Pharmaceutical Company (TAK) Income Statement

1,355 Followers

Takeda Pharmaceutical Company Income Statement

Last quarter (Q3 2025), Takeda Pharmaceutical Company's total revenue was ¥1.21T, an increase of 6.04% from the same quarter last year. In Q3, Takeda Pharmaceutical Company's net income was ¥105.51B. See Takeda Pharmaceutical Company’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 25Mar 24Mar 23Mar 22Mar 21
Total Revenue
¥ 4.58T¥ 4.26T¥ 4.03T¥ 3.57T¥ 3.20T
Gross Profit
¥ 3.00T¥ 2.83T¥ 2.78T¥ 2.46T¥ 2.20T
Operating Expenses
¥ 2.66T¥ 2.62T¥ 2.29T¥ 2.00T¥ 1.69T
Depreciation and Amortization
¥ 761.40B¥ 644.46B¥ 664.40B¥ 583.15B¥ 559.67B
EBITDA
¥ 1.21T¥ 1.14T¥ 1.28T¥ 1.18T¥ 983.72B
Operating Income
¥ 342.59B¥ 214.07B¥ 490.50B¥ 460.84B¥ 509.27B
Other Income/Expenses
¥ -167.50B¥ -161.28B¥ -115.42B¥ -158.27B¥ -143.03B
Pretax Income
¥ 175.08B¥ 52.79B¥ 375.09B¥ 302.57B¥ 366.24B
Net Income
¥ 107.93B¥ 144.07B¥ 317.02B¥ 230.06B¥ 376.00B
Per Share Metrics
Basic EPS
¥ 34.17¥ 46.05¥ 102.15¥ 73.57¥ 120.36
Diluted EPS
¥ 33.62¥ 45.58¥ 100.97¥ 72.94¥ 119.48
Weighted Average Shares Outstanding
 3.21B 3.13B 3.10B 3.13B 3.12B
Weighted Average Shares Outstanding (Diluted)
 3.21B 3.16B 3.14B 3.15B 3.15B
Currency in JPY

Takeda Pharmaceutical Company Earnings and Revenue History